[The treatment of patients with chronic persistent hepatitis B with interferon preparations].
Alpha-interferon preparations were injected intramuscularly in a single weekly dose 1.10(6) - 1.5.10(6) IU in courses lasting from 1 to 6 months to 37 patients with chronic persistent hepatitis B (CPHB) who entered a randomized clinicoimmunological trials. Except for moderate hyperfermentemia and HBs-antigenemia CPHB patients responsive to 3-4-month courses, alpha-interferon treatment of CPHB had no advantages over conventional therapy of the disease.
Kokoreva
L N
LN
Zmyzgova
A V
AV
Shalygina
N B
NB
D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013997:Time Factors
D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
O lechenii bol'nykh khronicheskim persistiruiushchim gepatitom B preparatami interferona.